It is a pharma private limited company based in Hyderabad, Telangana, India, established in 1999.
1999 | Hyderabad, Telangana, India | ActiveB E Immuno Sciences Private Limited, a active private limited company, was established on 24 May 1999 in Hyderabad, Telangana, India. Engaging in pharmaceutical retailers & distributors within the pharma sector, it holds CIN: U24230TG1999PTC031761. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹0.50 M and a paid-up capital of ₹0.10 M.
It upholds a compliant status. Its leadership includes Sridhar Pusapati Raju (Director), Mahima Datla (Director), Mantena Purnima (Additional Director). Past directors included Vijaykumar Datla. It holds ₹185.00 Cr open charges and ₹1.89 M settled loans. Its latest AGM occurred on 05 August 2024, with the balance sheet filed on 31 March 2024. It is based at 18/3, Azamabad, Hyderabad, Telangana, 500020.
U24230TG1999PTC031761
031761
24 May 1999
₹0.50 M
₹0.10 M
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into B E Immuno Sciences Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sridhar Pusapati Raju | Director | 24 May 1999 | Current |
| Mahima Datla | Director | 24 May 1999 | Current |
| Mantena Purnima | Additional Director | 12 Apr 2013 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 20 Mar 2013 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
B E Immuno Sciences Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 8.57% increase. The company also saw a substantial fall in profitability, with a 314.53% decrease in profit. The company's net worth observed a substantial decline by a decrease of 12.43%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2021, B E Immuno Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹1,850,000,000.00
₹1,892,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Jun 2024 | Others | ₹185.00 Cr | Open |
| 25 Nov 2011 | Panjab National Bank | ₹1.89 M | Satisfied |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with B E Immuno Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of B E Immuno Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped B E Immuno Sciences's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity A charge with Others of Rs. 1,850.00 M registered on 26 Jun 2024 with Charge ID 100956429 was modified on 07 Oct 2024. was completed.
Progress on B E Immuno Sciences Private Limited last Annual general meeting of members was held on 05 Aug 2024 as per latest MCA records. was documented.
A charge with Others amounted to Rs. 1,850.00 M with Charge ID 100956429 was registered on 26 Jun 2024. was recorded as a recent event.
The activity B E Immuno Sciences Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad. was completed.
Progress on A charge registered on 25 Nov 2011 via Charge ID 10320893 with Panjab National Bank was fully satisfied on 28 Aug 2014. was documented.
The activity Mantena Purnima was appointed as a Additional Director was appointed as a Additional Director on 12 Apr 2013 & has been associated with this company since 12 years 7 months . was completed.
The CIN of B E Immuno Sciences Private Limited is U24230TG1999PTC031761.
B E Immuno Sciences Private Limited is headquartered at 18/3, Azamabad, Hyderabad, Telangana, 500020.
B E Immuno Sciences Private Limited was incorporated on 24 May 1999.
The current directors of B E Immuno Sciences Private Limited are
The primary industry of B E Immuno Sciences Private Limited is Pharma.
B E Immuno Sciences Private Limited is unlisted.
The authorized capital of B E Immuno Sciences Private Limited is ₹0.50 M, and the paid-up capital is ₹0.10 M.
The compliance status of B E Immuno Sciences Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX